Literature DB >> 15772744

Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease.

Haruo Hanyu, Yuriko Tanaka, Soichiro Shimizu, Hirofumi Sakurai, Toshiko Iwamoto, Kimihiko Abe.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15772744     DOI： 10.1007/s00415-005-0611-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

Review 1.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

2.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

3.  The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings.

Authors:  H Förstl; A Burns; P Luthert; N Cairns; R Levy
Journal:  Br J Psychiatry       Date:  1993-03       Impact factor: 9.319

4.  Cholinergic dysfunction in diseases with Lewy bodies.

Authors:  P Tiraboschi; L A Hansen; M Alford; M N Sabbagh; B Schoos; E Masliah; L J Thal; J Corey-Bloom
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 5.  Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?

Authors:  P Liberini; A Valerio; M Memo; P F Spano
Journal:  Trends Pharmacol Sci       Date:  1996-04       Impact factor: 14.819

6.  Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

Authors:  I G McKeith; C G Ballard; R H Perry; P G Ince; J T O'Brien; D Neill; K Lowery; E Jaros; R Barber; P Thompson; A Swann; A F Fairbairn; E K Perry
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

7.  Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies.

Authors:  P J Langlais; L Thal; L Hansen; D Galasko; M Alford; E Masliah
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

8.  MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report.

Authors:  M Sasaki; S Ehara; Y Tamakawa; S Takahashi; H Tohgi; A Sakai; T Mita
Journal:  AJNR Am J Neuroradiol       Date:  1995 Nov-Dec       Impact factor: 3.825

9.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

Authors:  E K Perry; V Haroutunian; K L Davis; R Levy; P Lantos; S Eagger; M Honavar; A Dean; M Griffiths; I G McKeith
Journal:  Neuroreport       Date:  1994-03-21       Impact factor: 1.837

10.  Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients.

Authors:  Yuriko Tanaka; Haruo Hanyu; Hirofumi Sakurai; Masaru Takasaki; Kimihiko Abe
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959
View more
  11 in total

1.  Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies.

Authors:  Zuzana Nedelska; Tanis J Ferman; Bradley F Boeve; Scott A Przybelski; Timothy G Lesnick; Melissa E Murray; Jeffrey L Gunter; Matthew L Senjem; Prashanti Vemuri; Glenn E Smith; Yonas E Geda; Jonathan Graff-Radford; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Clifford R Jack; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-07-15       Impact factor: 4.673

2.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack
Journal:  Brain       Date:  2007-01-31       Impact factor: 13.501

3.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.

Authors:  Michel J Grothe; Christina Schuster; Florian Bauer; Helmut Heinsen; Johannes Prudlo; Stefan J Teipel
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

4.  Rates of cerebral atrophy differ in different degenerative pathologies.

Authors:  Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs
Journal:  Brain       Date:  2007-03-08       Impact factor: 13.501

5.  Analysis of the substantia innominata volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and Alzheimer's disease.

Authors:  Hee Jin Kim; Ji Eun Lee; Soo Jeong Shin; Young Ho Sohn; Phil Hyu Lee
Journal:  J Mov Disord       Date:  2011-10-30

6.  Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis.

Authors:  Wen-Ying Ma; Min-Jie Tian; Qun Yao; Qian Li; Fan-Yu Tang; Chao-Yong Xiao; Jing-Ping Shi; Jiu Chen
Journal:  CNS Neurosci Ther       Date:  2021-12-06       Impact factor: 5.243

Review 7.  Neuroimaging in aging and neurologic diseases.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Handb Clin Neurol       Date:  2019

Review 8.  Neuroimaging characteristics of dementia with Lewy bodies.

Authors:  Elijah Mak; Li Su; Guy B Williams; John T O'Brien
Journal:  Alzheimers Res Ther       Date:  2014-04-09       Impact factor: 6.982

9.  Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL-VBM study.

Authors:  Sean J Colloby; Greg J Elder; Riham Rabee; John T O'Brien; John-Paul Taylor
Journal:  Int J Geriatr Psychiatry       Date:  2016-05-19       Impact factor: 3.485

10.  Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology.

Authors:  Kyota Fujita; Hidenori Homma; Kanoh Kondo; Masashi Ikuno; Hodaka Yamakado; Kazuhiko Tagawa; Shigeo Murayama; Ryosuke Takahashi; Hitoshi Okazawa
Journal:  eNeuro       Date:  2018-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.